contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


virogates-capital-raise-of-dkk-139-million-and-issue-of-3097047-new-shares-have-been-registered

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Virogates er aktiv inden for medicinsk teknologi. I dag udføres forretningsdrift inden for forskning og udvikling af biomarkører og diagnostiske instrumenter til sundhedsindustrien. Produkterne sælges under forskellige mærker og bruges til identifikation, analyse og videre behandling af sygdomme, hovedsageligt hjerte -kar -sygdomme, kræft og neurologiske sygdomme. Virksomheden blev etableret i 2001 og har sit hovedkontor med beliggenhed i Birkerød.

Virogates

19.12.2023 16:03:14 CET | ViroGates | Changes in share capital and votesCOMPANY ANNOUNCEMENT - No. 23-2023 - 19 December 2023BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”) ...

19.12.2023 16:03:14 CET | ViroGates | Changes in share capital and votesCOMPANY ANNOUNCEMENT - No. 23-2023 - 19 December 2023BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”) announces that the capital raise of approximately DKK 13.9 million has been completed. The issue of 3,097,047 new shares at a price of DKK 4.5 per share has been registered with the Danish Business Authority.Prior to the increase, the Company’s share capital amounted to DKK 3,350,507, consisting of 3,350,507 shares of nominally DKK 1 each. After the nominal increase of DKK 3,097,047, the Company’s share capital now amounts to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each.The change in share capital is reflected in the Company’s articles of association available on the Company’s website.ViroGates further expects that the first day of trading of the new shares on Nasdaq First North Growth Market Denmark is 21 December 2023.For further information, please contact:ViroGates A/S:CEO, Jakob KnudsenTel. (+45) 2226 1355, email: <a href="mailto:jk@virogates.com">jk@virogates.com</a>Certified Advisor:Västra Hamnen Corporate FinancePer LönnTel. (+46) 40 200 250, email: <a href="mailto:per.lonn@vhcorp.se">ca@vhcorp.se</a>About ViroGatesViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs, and empower clinical staff.The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a href="http://www.virogates.com">www.virogates.com</a>.<h4>Disclosure regulation</h4>Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.<h4>Contacts</h4><ul> <li> Jakob Knudsen, CEO, +45 2226 1355, <a href="mailto:jk@virogates.com">jk@virogates.com</a> </li></ul><h4>Attachments</h4><ul> <li> <a href="https://via.ritzau.dk/ir-files/13559605/8028/12261/20231219%20-ViroGates%20Company%20ann.%2023.pdf">20231219 -ViroGates Company ann. 23.pdf</a> </li></ul>

ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered

Disclosure regulation

Contacts

Attachments

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!